WO2000050022A3 - Treatment regimen for hormone-sensitive cancers - Google Patents

Treatment regimen for hormone-sensitive cancers Download PDF

Info

Publication number
WO2000050022A3
WO2000050022A3 PCT/US2000/004879 US0004879W WO0050022A3 WO 2000050022 A3 WO2000050022 A3 WO 2000050022A3 US 0004879 W US0004879 W US 0004879W WO 0050022 A3 WO0050022 A3 WO 0050022A3
Authority
WO
WIPO (PCT)
Prior art keywords
hormone
therapy
treatment regimen
estramustine
months
Prior art date
Application number
PCT/US2000/004879
Other languages
French (fr)
Other versions
WO2000050022A2 (en
Inventor
Larry Helson
Original Assignee
Napro Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napro Biotherapeutics Inc filed Critical Napro Biotherapeutics Inc
Priority to CA002366697A priority Critical patent/CA2366697A1/en
Priority to EP00914713A priority patent/EP1154819A2/en
Priority to JP2000600634A priority patent/JP2002537328A/en
Priority to AU36067/00A priority patent/AU3606700A/en
Publication of WO2000050022A2 publication Critical patent/WO2000050022A2/en
Publication of WO2000050022A3 publication Critical patent/WO2000050022A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides for a novel schedule and dosage regimen of the combination paclitaxel-estramustine and chemical or surgical hormone depletion to treat patients with advanced breast cancer who have not received previous therapy and are candidates for hormonal therapy. This invention differs from all current treatment strategies by the intercalation of cytotoxic chemotherapy (preferably paclitaxel and estramustine) at a specified interval (two months; range 2 weeks to 6 months) after initiation of hormone depletion therapy.
PCT/US2000/004879 1999-02-26 2000-02-25 Treatment regimen for hormone-sensitive cancers WO2000050022A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002366697A CA2366697A1 (en) 1999-02-26 2000-02-25 Treatment regimen for hormone-sensitive cancers
EP00914713A EP1154819A2 (en) 1999-02-26 2000-02-25 Treatment regimen for hormone-sensitive cancers
JP2000600634A JP2002537328A (en) 1999-02-26 2000-02-25 Treatment regimen for hormone-sensitive cancer
AU36067/00A AU3606700A (en) 1999-02-26 2000-02-25 Treatment regimen for hormone-sensitive cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12209499P 1999-02-26 1999-02-26
US60/122,094 1999-02-26

Publications (2)

Publication Number Publication Date
WO2000050022A2 WO2000050022A2 (en) 2000-08-31
WO2000050022A3 true WO2000050022A3 (en) 2001-02-01

Family

ID=22400570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/004879 WO2000050022A2 (en) 1999-02-26 2000-02-25 Treatment regimen for hormone-sensitive cancers

Country Status (5)

Country Link
EP (1) EP1154819A2 (en)
JP (1) JP2002537328A (en)
AU (1) AU3606700A (en)
CA (1) CA2366697A1 (en)
WO (1) WO2000050022A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067498A1 (en) * 2005-12-06 2007-06-14 Cell Therapeutics, Inc. Estrogen cancer therapy

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
WO1994013277A2 (en) * 1992-12-05 1994-06-23 Imperial Cancer Research Technology Limited Use of dinaphthalenes compounds as antiproliferative agents
WO1997000683A1 (en) * 1995-06-23 1997-01-09 Georgetown University Progesterone analogs to reverse multidrug resistance
US5676978A (en) * 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
WO1998014188A1 (en) * 1996-10-04 1998-04-09 Ilex Oncology, Inc. Dfmo and taxol for the treatment or prevention of breast cancer
WO1998025603A1 (en) * 1996-12-13 1998-06-18 Ilex Oncology, Inc. Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer
WO1998032440A1 (en) * 1997-01-28 1998-07-30 The Procter & Gamble Company Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator
WO1998051303A1 (en) * 1997-05-16 1998-11-19 The Procter & Gamble Company Hiv and cancer treatment
FR2775187A1 (en) * 1998-02-25 1999-08-27 Novartis Ag Treatment of proliferative diseases, especially drug-resistant cancers - with epothilone B

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US5676978A (en) * 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
WO1994013277A2 (en) * 1992-12-05 1994-06-23 Imperial Cancer Research Technology Limited Use of dinaphthalenes compounds as antiproliferative agents
WO1997000683A1 (en) * 1995-06-23 1997-01-09 Georgetown University Progesterone analogs to reverse multidrug resistance
WO1998014188A1 (en) * 1996-10-04 1998-04-09 Ilex Oncology, Inc. Dfmo and taxol for the treatment or prevention of breast cancer
WO1998025603A1 (en) * 1996-12-13 1998-06-18 Ilex Oncology, Inc. Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer
WO1998032440A1 (en) * 1997-01-28 1998-07-30 The Procter & Gamble Company Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator
WO1998051303A1 (en) * 1997-05-16 1998-11-19 The Procter & Gamble Company Hiv and cancer treatment
FR2775187A1 (en) * 1998-02-25 1999-08-27 Novartis Ag Treatment of proliferative diseases, especially drug-resistant cancers - with epothilone B

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ATIENZA, DANIEL M. ET AL: "Phase II study of oral etoposide for patients with advanced breast cancer", CANCER (PHILADELPHIA) (1995), 76(12), 2485-90, XP000957566 *
BUZDAR ET AL: "Treatment of Advanced Breast Cancer with Aminoglutethimide after Therapy with Tamoxifen", CANCER, vol. 50, 1982, pages 1708 - 1712, XP000957573 *
DAVIDSON, NEVILLE G.: "Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience", SEMIN. ONCOL. (1996), 23(5, SUPPL. 11), 6-10, XP000957565 *
FURUYA, YUZO ET AL: "Apoptosis of androgen-independent mammary and prostate cell lines induced by topoisomerase inhibitors: common pathway of gene regulation", ANTICANCER RES. (1997), 17(3C), 2089-2093, XP000957553 *
KOHLER, UWE ET AL: "Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study", SEMIN. ONCOL. (1997), 24(5, SUPPL. 17), 40-43, XP000957561 *

Also Published As

Publication number Publication date
WO2000050022A2 (en) 2000-08-31
AU3606700A (en) 2000-09-14
EP1154819A2 (en) 2001-11-21
JP2002537328A (en) 2002-11-05
CA2366697A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
IL244727A0 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA03003960A (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders.
MXPA05012155A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases.
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
MXPA03007837A (en) Compositions for delivering bisphosphonates.
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
HK1106736A1 (en) Combination therapy comprising anti-cd20 and anti-cd40 antibodies for the treatment of b cell-related cancers
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
WO2003106381A3 (en) Human adam-10 inhibitors
HK1069335A1 (en) Use of anastrozole for the treatment of post-menopausal women having early breast cancer
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
EP0934065A4 (en) Pharmaceutical compounds
TW200501945A (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP1453812A4 (en) Cytotoxic agents
EP1420827B8 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
YU18099A (en) Hormonal composition consisting of an oestrogen compound and of a progestational compound
GB0020504D0 (en) Therapeutic method
HUP0302296A2 (en) Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
WO2000050022A3 (en) Treatment regimen for hormone-sensitive cancers
EP0869786A4 (en) Pharmaceutical compounds
WO2000050021A3 (en) Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started
NZ516564A (en) Cancer therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2366697

Country of ref document: CA

Ref country code: CA

Ref document number: 2366697

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 600634

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 36067/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000914713

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000914713

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000914713

Country of ref document: EP